Hypertension society splits with journal in CME dispute

Share this article:

The American Society of Hypertension (ASH) has ended its 16-year relationship with the American Journal of Hypertension (AJH) in a dispute over the control and credibility of the society's continuing medical education symposia.
AJH's editor John Laragh made the announcement in an editorial appearing in the journal's July issue.
Laragh, a researcher at Cornell University's Weill Medical College, has accused the society's leaders of being improperly influenced by financial ties to the pharmaceutical an article in Friday's Wall Street Journal said.
In an email to sent ASH members in May, Laragh said the society's CME agenda had become "unacceptably dominated" by members "heavily involved in pharma marketing for personal gain."
Laragh alleged the changes at ASH occurred after Thomas Giles, a hypertension researcher, became president of the society in 2004, the newspaper article said.
Giles denied the charge telling the Journal, "We have the same sort of fire wall that most organizations build." Giles added that during his tenure at least one physician had been sanctioned and reprimanded by letter for giving a "commercially biased presentation."
Meanwhile, the society will seek new "official publications" to communicate scientific developments to ASH members, Giles said. The new "publications" will have "complete editorial independence," Giles said, and ASH will provide "appropriate editorial oversight to make sure they serve the society's mission."


Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Media

Five things for pharma marketers to know: Wednesday, October 22

Five things for pharma marketers to know: ...

Novo partners with YouTube star for diabetes vids; hedge fund wants Amgen to split up; J&J ramps up Ebola vaccine production.

Mucinex gets a revamp

Mucinex gets a revamp

After 10 years of "Mucinex In. Mucus Out," the congestion-relief treatment gets a new look from Reckitt Beckinser's recently appointed AOR McCann New York.

Mixed reaction to a health-centric Facebook feature

Mixed reaction to a health-centric Facebook feature

The ACLU is among those questioning the positives of the rumored healthcare effort.